NASDAQ$HRMY
Harmony Biosciences Holdings Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Harmony Biosciences' Q4 2022 financial performance was reported, featuring revenue growth and advancements in clinical development programs.
Harmony Biosciences reported a strong Q4 2022, with net product revenues reaching $128.3 million, a 40.7% increase compared to the same period in 2021. GAAP net income for the quarter was $48.5 million, or $0.79 per diluted share, while non-GAAP adjusted net income was $61.9 million, or $1.01 per diluted share.
- Net product revenues for Q4 2022 were $128.3 million, up from $91.2 million in the same period in 2021.
- GAAP net income for Q4 2022 was $48.5 million, or $0.79 per diluted share, compared to $22.7 million, or $0.38 per diluted share, for the same period in 2021.
- Non-GAAP adjusted net income for Q4 2022 was $61.9 million, or $1.01 per diluted share, compared to $30.4 million, or $0.50 per diluted share, for the same period in 2021.
- The average number of patients on WAKIX increased to approximately 4,900 for the quarter ended December 31, 2022.
Headline financials
Revenue & EPS history
Harmony Biosciences · Revenue · Quarterly
$128M
Revenue by segment
Harmony Biosciences · $128M total across 1 segment · Q4 2022
- WAKIX Net Product Revenue$128M+40.7%100.0%
Forward guidance
Harmony remains confident in the ongoing performance of WAKIX and focuses on advancing life cycle management programs for pitolisant and acquiring new assets to build out the pipeline to drive additional growth.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+1.3%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+6.0%
Avg return
30 days after
54%
14 / 26 earnings
Positive
+24.4%
Q3 2023
Best reaction
-15.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | -8.0% | -1.8% | |
| Q4 2025 | +2.6% | +6.2% | +2.1% | |
| Q3 2025 | -1.6% | -5.1% | +18.1% | |
| Q1 2025 | +7.0% | +13.7% | +16.9% | |
| Q4 2024 | +8.2% | -1.0% | -2.4% | |
| Q3 2024 | -5.5% | -7.5% | +0.0% | |
| Q2 2024 | +8.5% | +9.4% | +15.0% | |
| Q1 2024 | +3.5% | +7.9% | -1.3% | |
| Q4 2023 | -1.5% | +1.5% | +0.9% | |
| Q3 2023 | +24.4% | +31.5% | +47.4% | |
| Q2 2023 | -7.9% | -5.0% | +2.5% | |
| Q1 2023 | +9.9% | +9.5% | +5.0% | |
| Q4 2022 | -6.1% | -8.0% | -15.2% | |
| Q3 2022 | +12.5% | +13.2% | +15.4% | |
| Q2 2022 | +6.3% | +6.6% | -7.8% | |
| Q1 2022 | -15.1% | -21.9% | -5.0% | |
| Q4 2021 | +5.6% | +6.1% | +31.5% | |
| Q3 2021 | +0.1% | -0.1% | -9.3% | |
| Q2 2021 | +13.9% | +20.1% | +41.4% | |
| Q1 2021 | +1.2% | +4.0% | +21.8% | |
| Q1 2020 | +1.2% | +4.0% | +21.8% | |
| Q2 2020 | -4.1% | +11.4% | -2.1% | |
| Q4 2020 | -4.1% | +11.4% | -2.1% | |
| Q3 2020 | -6.8% | -7.4% | -12.0% | |
| Q4 2019 | -6.8% | -7.4% | -12.0% | |
| Q3 2019 | -6.8% | -7.4% | -12.0% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro